The China Alzheimer’s disease diagnostics market
was valued at USD 287.76 million in 2023 and is projected to reach USD
631.73 million by 2030, expanding at a compound annual growth rate
(CAGR) of 12.1% from 2024 to 2030. This strong market growth is being
driven by several converging factors that are reshaping the landscape of
neurological diagnostics in China.
One of the primary growth
drivers is the increasing prevalence of Alzheimer’s disease (AD) in
China, largely due to the country’s rapidly aging population. As the
number of elderly individuals rises, so does the incidence of cognitive
disorders, particularly Alzheimer’s disease, which has become a major
public health concern.
Another key factor supporting market
expansion is the growing reliance on biomarkers for early and accurate
disease diagnosis. Biomarkers such as amyloid beta and tau proteins are
increasingly being used to identify, track, and monitor disease
progression, offering clinicians more precise tools than traditional
symptom-based assessments. This trend is particularly relevant in China,
where early detection is crucial in managing the rising disease burden.
In
addition, the widespread adoption of personalized diagnostic solutions
is propelling demand for tailored approaches to Alzheimer’s detection
and monitoring. Precision diagnostics help in developing customized
treatment plans, improving outcomes and quality of life for patients.
The role of technological advancements in medical imaging cannot be
understated. Innovations in imaging modalities such as PET (positron
emission tomography) and MRI (magnetic resonance imaging) are enabling
non-invasive, accurate, and early diagnosis of Alzheimer’s-related brain
changes. These technologies are becoming more widely adopted in
hospitals, research institutes, and specialized diagnostic centers
across China.
Furthermore, the increased government investment in
healthcare infrastructure and escalating research and development
(R&D) activities in neurology and diagnostics are providing a
supportive environment for market growth. China’s health authorities are
actively prioritizing neurodegenerative disease research and funding
initiatives that enhance diagnostic capabilities.
Key Market Trends & Insights:
- In
2023, imaging techniques held the largest revenue share of 41.40%,
reflecting the critical role of neuroimaging in identifying brain
changes associated with Alzheimer’s. The demand for technologies such as
PET and MRI scans is growing rapidly, especially as clinicians seek
early and definitive diagnosis.
- The biomarkers segment is
anticipated to witness the fastest growth, registering a CAGR of 15.7%
during the forecast period. The rising awareness and adoption of
biomarker testing through cerebrospinal fluid (CSF) analysis or
blood-based tests underscore its increasing importance in monitoring
disease progression and predicting therapeutic responses.
- The
diagnosis segment dominated the market in 2023, accounting for 53.49% of
total market share. This reflects the growing demand for accurate
diagnostic solutions as China’s elderly population grows and the
healthcare system becomes more proactive in detecting neurodegenerative
diseases at early stages.
- The expansion of public awareness
campaigns, government health initiatives, and collaborations with NGOs
and healthcare providers have further increased public knowledge and
screening rates, contributing to the growth of diagnostic services.
- In
terms of end users, academic and research institutes emerged as the
leading segment in 2023, contributing 47.02% of the market share. This
dominance is largely due to the surge in research studies and clinical
trials focusing on neurological diseases over the past decade.
- These
institutions are playing a pivotal role in innovative diagnostics
research, validating new biomarkers, and testing emerging imaging
techniques, which makes them critical contributors to the evolution of
Alzheimer’s diagnostics in China.
Order a free sample PDF of the China Alzheimer’s Disease Diagnostics Market Intelligence Study, published by Grand View Research.
Market Size & Forecast:
- 2023 Market Size: USD 287.76 Million
- 2030 Projected Market Size: USD 631.73 Million
- CAGR (2024-2030): 12.1%
Key Companies & Market Share Insights:
Some
key players operating in the market include Quest Diagnostics
Incorporated, Abbott, F. Hoffmann-La Roche Ltd., Eli Lily, Bio-Rad
Laboratories, Inc., Eisai Co Ltd, Clario, and others. The market is
highly competitive, with many manufacturers accounting for most of the
share. New source developments, mergers and acquisitions, and
collaborations are major strategies these players adopt to counter stiff
competition.
Key Players
- Quest Diagnostics
- Labcorb
- C2N diagnostics
- FujireBio
- Bristol Myers Squibb
- Hoffmann-La Roche
- Quanterix
- Sysmex
- Lantheus
- Siemens Healthineers
- Life Molecular Imaging
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion:
In
conclusion, the China Alzheimer’s disease diagnostics market is
undergoing significant transformation, driven by an aging population,
early-stage disease burden, government support, technological
innovation, and major pharmaceutical advancements such as the
introduction of LEQEMBI. As early detection becomes increasingly central
to Alzheimer’s management, demand for advanced diagnostics tools from
biomarkers to imaging will continue to expand, ensuring robust market
growth through 2030.
Comments
Post a Comment